While human NPM1 mutations are most often observed in de novo AML, several studies have shown that NPM1 mutations can be present in MDS or MDS/myeloproliferative neoplasm (MPN) prior to blast counts reaching the threshold for AML diagnosis [29, 30]. Here, NPM1 is linked to myeloproliferative neoplasm.